Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RetroNectin-activated killer cells
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
RetroNectin-activated killer (RAK) cells are an adoptive cell immunotherapy developed by the Chinese PLA General Hospital for the treatment of advanced gastric cancer. These cells are autologous peripheral blood lymphocytes (or in some study arms, derived from human umbilical cord blood) that are expanded and activated ex vivo using a combination of RetroNectin (a recombinant chimeric fibronectin fragment), anti-CD3 monoclonal antibodies, and cytokines such as Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ). This activation process enhances the proliferative capacity and anti-tumor cytotoxicity of the cells compared to conventional cytokine-induced killer (CIK) cells. RAK cells primarily consist of CD8+ T cells and natural killer T (NKT) cells, which exert non-MHC-restricted cytolytic activity against tumor cells. The therapy is currently being evaluated in Phase 2 clinical trials in combination with the chemotherapy agent TAS-102 (trifluridine/tipiracil) for patients with recurrent or metastatic gastric cancer who have failed frontline therapy.
- Other names
- RetroNectin active Killer cellsRAK cell therapy
Beyond the preview
Go deeper on RetroNectin-activated killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RetroNectin-activated killer cells.